Auna S.A. Earnings Call Transcripts
Fiscal Year 2025
-
Stabilized Mexico operations and strong Peru performance offset earlier setbacks, with consolidated revenue up 6% and adjusted net income more than tripling year-over-year. Guidance for 2026 targets 12% growth in both revenue and EBITDA, supported by new contracts, cost controls, and a strengthened capital structure.
-
Flat consolidated results as Peru and Colombia delivered strong growth, offsetting Mexico's 12% revenue decline due to operational challenges. Debt refinancing improved the capital structure, and a new partnership with Sojitz supports a $500M investment plan in Mexico, with growth expected to resume in 2026.
-
Consolidated FX-neutral EBITDA grew 5% year-over-year, with Mexico, Peru, and Colombia all contributing. Adjusted net income surged, margins held steady, and risk-sharing models expanded in Colombia. Near-term growth faces uncertainty from Mexico's trade issues and Colombia's payer risks.
-
First quarter results were mixed, with Peru delivering strong growth and Mexico facing operational setbacks that led to lower volumes and revenue. Colombia saw improved cash flow from risk-sharing models, while the company maintained a solid financial position and remains focused on recovery and expansion.
Fiscal Year 2024
-
Achieved strong 2024 results with 20% adjusted EBITDA growth, led by Peru and Mexico, while Colombia faced payer-related challenges. Deleveraging continued, with net debt/EBITDA at 3.6x and robust free cash flow. 2025 outlook is positive but cautious due to Colombia's uncertainties.
-
Adjusted EBITDA rose 23% year-over-year, with strong growth in Mexico and Peru and cautious expansion in Colombia. Net debt to Adjusted EBITDA improved to 3.7x, and guidance for 20% FX neutral EBITDA growth is reaffirmed. OncoMexico's pilot phase is progressing well, with robust B2B interest.
-
Q2 2024 saw accelerated growth, with revenue up 13% and adjusted EBITDA up 25% year-over-year (FX neutral), driven by strong results in Peru and Colombia and improving performance in Mexico. OncoMexico launched, and deleveraging continued, with net debt/EBITDA at 4.13x.